{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:46:49Z","timestamp":1787024809265,"version":"build-2736575974"},"reference-count":104,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Hematol. Oncol."],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.2217\/ijh.13.3","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T11:22:56Z","timestamp":1360927376000},"page":"61-70","source":"Crossref","is-referenced-by-count":5,"title":["Current Approaches to the Initial Treatment of Symptomatic Multiple Myeloma"],"prefix":"10.2217","volume":"2","author":[{"given":"Jagoda K","family":"Jasielec","sequence":"first","affiliation":[{"name":"The University of Chicago Medical Center, Department of Medicine, Section of Hematology\/Oncology, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"The University of Chicago Medical Center, Department of Medicine, Section of Hematology\/Oncology, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,2,15]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-297325"},{"key":"e_1_3_3_3_1","first-page":"CD004023","article-title":"Early versus deferred treatment for early stage multiple myeloma","volume":"1","author":"He Y","year":"2003","unstructured":"He Y , WheatleyK, ClarkO, GlasmacherA, RossH, DjulbegovicB. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst. Rev.1, CD004023 (2003).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"e_1_3_3_4_1","first-page":"846","article-title":"Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.","volume":"87","author":"Boccadoro M","year":"2002","unstructured":"Boccadoro M , PalumboA, BringhenSet al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 87(8), 846\u2013850 (2002).","journal-title":"Haematologica"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.174"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500464104"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0034"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.160"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.02.003"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.127"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405985"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0603"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038430"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8545"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12106"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-201053"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4250"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.5370"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.567316"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11534"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23546"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.9721"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.009100"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370460"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.116"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222539"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-303487"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.077"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404442"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408898"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355081"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"Nooka AK KaufmanJL BeheraMet al. The improved efficacy of bortezomib containing induction regimens (BCIR) versus non-bortezomib containing induction regimens (NBCIR) in transplant- eligible patients with multiple myeloma (MM): meta-analysis of Phase III randomized controlled trials (RCTs). Blood (ASH Annual Meeting Abstracts) 118 Abstract 3994 (2011).","DOI":"10.1182\/blood.V118.21.3994.3994"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-334755"},{"key":"e_1_3_3_42_1","doi-asserted-by":"crossref","unstructured":"Mikhael JR ReederCB LibbyENet al. A Phase I\/II trial of cyclophosphamide carfilzomib thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. J. Clin. Oncol. 30(Suppl.) Abstract 8010 (2012).","DOI":"10.1200\/jco.2012.30.15_suppl.8010"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.731"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241737"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1301"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0551"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5807"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21191"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705580"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02976.x"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.51"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_3_3_55_1","doi-asserted-by":"crossref","unstructured":"Boccadoro M CavalloF NaglerAet al. Melphalan\/prednisone\/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed patients: a Phase III study. J. Clin. Oncol. 29(Suppl.) Abstract 8020 (2011).","DOI":"10.1200\/jco.2011.29.15_suppl.8020"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3131"},{"key":"e_1_3_3_57_1","doi-asserted-by":"crossref","unstructured":"Siegel DS JacobusS RajkumarSVet al. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 randomized clinical trial. Blood 11 Abstract 28 (2010).","DOI":"10.1182\/blood.V116.21.38.38"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61537-2"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2509"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0889"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-337329"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7312"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70243-1"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3869"},{"key":"e_1_3_3_66_1","first-page":"S45","article-title":"Tandem autologous transplantation versus autologous plus reduced-intensity conditioning allogeneic transplantation in the managmement of newly diagnosed multiple myeloma: meta-analysis of all prospective trials with biological randomization","volume":"47","author":"Costa L","year":"2012","unstructured":"Costa L , ArmesonK, HillE. Tandem autologous transplantation versus autologous plus reduced-intensity conditioning allogeneic transplantation in the managmement of newly diagnosed multiple myeloma: meta-analysis of all prospective trials with biological randomization. Bone Marrow Transplantation47, S45 (2012).","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_3_3_67_1","first-page":"S44","article-title":"Comparative efficacy of tandem autologous-autologous versus tandem autologous-reduced intensity allogeneic haematopoietic cell transplantation in multiple myeloma: results of a systemic review and meta-analysis","volume":"47","author":"Kharfan-Dajaba M","year":"2012","unstructured":"Kharfan-Dajaba M , HamadaniM, ReljicT, BensingerW, DjulbegovicB, KumarA. Comparative efficacy of tandem autologous-autologous versus tandem autologous-reduced intensity allogeneic haematopoietic cell transplantation in multiple myeloma: results of a systemic review and meta-analysis. Bone Marrow Transplantation47, S44 (2012).","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393801"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065464"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149427"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0948"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1610"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237974"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01524.x"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341669"},{"key":"e_1_3_3_78_1","doi-asserted-by":"crossref","unstructured":"San Miguel JF SchlagR KhuagevaNKet al. Continued overall survival benefit after 5 years\u2018 follow-up with bortezomib\u2013melphalan\u2013 prednisone (VMP) versus melphalan\u2013prednisone in patients with previously untreated multiple myeloma and no increased risk of second primary malignancies: final results of the Phase 3 VISTA trial. Blood (ASH Annual Meeting Abstracts) 118 Abstract 476 (2011).","DOI":"10.1182\/blood.V118.21.476.476"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70187-X"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_3_3_82_1","doi-asserted-by":"crossref","unstructured":"Palumbo A BringhenS CavalliMet al. Bortezomib melphalan prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: updated follow-up and impact of prognostic factors. Blood (ASH Annual Meeting Abstracts) 116 Abstract 620 (2010).","DOI":"10.1182\/blood.V116.21.620.620"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239046"},{"key":"e_1_3_3_85_1","doi-asserted-by":"crossref","unstructured":"Kolb B HulinC CaillotDet al. Phase I\/II stude of carfilzomib plus melphalan\u2013prednisone (CMP) in elderly patients with de novo multiple myeloma. J. Clin. Oncol. 30(Suppl.) Abstract 8009 (2012).","DOI":"10.1200\/jco.2012.30.15_suppl.8009"},{"key":"e_1_3_3_86_1","doi-asserted-by":"crossref","unstructured":"Palumbo A BringhenS VillaniOet al. Carfilzomib cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) Patients. ASH (Annual Meeting Abstracts) 120 Abstract 730 (2012).","DOI":"10.1182\/blood.V120.21.730.730"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332320"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159624"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1060"},{"key":"e_1_3_3_90_1","volume-title":"Presented at: 13th International Myeloma Workshop","author":"Mellqvist U","unstructured":"Mellqvist U , GimsingP, HjertnerOet al. Improved progression free survival with bortezomib consolidation after high dose melphalan: results of a randomized Phase III trial. Presented at: 13th International Myeloma Workshop, Paris, France, 3\u20136 May 2011."},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7172"},{"key":"e_1_3_3_92_1","doi-asserted-by":"crossref","unstructured":"Roussel M RobillardN MoreauPet al. Bortezomib lenalidomide and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients; updated results of the IFM 2008 Phase II VRD intesive program. Blood (ASH Annual Meeting Abstracts) 118 Abstract 1872 (2011).","DOI":"10.1182\/blood.V118.21.1872.1872"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053583"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145235"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6081"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-357038"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_3_3_100_1","doi-asserted-by":"crossref","unstructured":"Palumbo A DelforgeM CatalanoJet al. A Phase 3 study evaluating the efficacy and safety of lenalidomide comibned with melphalan and prednisone in patients >65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens. Blood (ASH Annual Meeting Abstracts) 116 Abstract 622 (2010).","DOI":"10.1182\/blood.V116.21.622.622"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-427815"},{"key":"e_1_3_3_102_1","doi-asserted-by":"crossref","unstructured":"Palumbo A BringhenS RossiDet al. Overall survival benefit for bortezomib\u2013melphalan\u2013prednisone\u2013thalidomide followed by maintenance with bortezomib\u2013thalidomide (VMPT-VT) versus bortezomib\u2013melphalan\u2013prednisone (VMP) in newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 120 Abstract 200 (2012).","DOI":"10.1182\/blood.V120.21.200.200"},{"key":"e_1_3_4_2_1","unstructured":"National Comprehensive Cancer Network. Multiple myeloma: primary treatment and follow-up. Version 1. 2013. www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"e_1_3_4_3_1","unstructured":"National Comprehensive Cancer Network: NCCN Categories of Evidence and Consensus. www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site"},{"key":"e_1_3_4_4_1","unstructured":"Intergroupe Fraconphone du Myelome\/Dana Farber Cancer Institute. Collaborative translational research in multiple myeloma. www.ifm-dfci.org\/trial.html"}],"container-title":["International Journal of Hematologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/ijh.13.3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:26:30Z","timestamp":1715984790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/ijh.13.3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.2217\/ijh.13.3"],"URL":"https:\/\/doi.org\/10.2217\/ijh.13.3","relation":{},"ISSN":["2045-1393","2045-1407"],"issn-type":[{"value":"2045-1393","type":"print"},{"value":"2045-1407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}